GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

derivative 17 [Nakahata et al., 2018]   Click here for help

GtoPdb Ligand ID: 9804

Synonyms: example 65 [WO2011078360] [7]
PDB Ligand
Compound class: Synthetic organic
Comment: Derivative 17 is a potent GPR52 agonist with in vivo activity [1]. GPR52 agonists are being investigated as novel anti-psychotics.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 5
Hydrogen bond donors 3
Rotatable bonds 9
Topological polar surface area 115.1
Molecular weight 489.13
XLogP 3.24
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES OCCNC(=O)c1c(C)nn(c1CO)c1cccc2c1sc(c2)Cc1cccc(c1)C(F)(F)F
Isomeric SMILES OCCNC(=O)c1c(C)nn(c1CO)c1cccc2c1sc(c2)Cc1cccc(c1)C(F)(F)F
InChI InChI=1S/C24H22F3N3O3S/c1-14-21(23(33)28-8-9-31)20(13-32)30(29-14)19-7-3-5-16-12-18(34-22(16)19)11-15-4-2-6-17(10-15)24(25,26)27/h2-7,10,12,31-32H,8-9,11,13H2,1H3,(H,28,33)
InChI Key VJMRKWPMFQGIPI-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
References
1. Nakahata T, Tokumaru K, Ito Y, Ishii N, Setoh M, Shimizu Y, Harasawa T, Aoyama K, Hamada T, Kori M et al.. (2018)
Design and synthesis of 1-(1-benzothiophen-7-yl)-1H-pyrazole, a novel series of G protein-coupled receptor 52 (GPR52) agonists.
Bioorg Med Chem, 26 (8): 1598-1608. [PMID:29478803]
2. Nishiyama K, Suzuki H, Harasawa T, Suzuki N, Kurimoto E, Kawai T, Maruyama M, Komatsu H, Sakuma K, Shimizu Y et al.. (2017)
FTBMT, a Novel and Selective GPR52 Agonist, Demonstrates Antipsychotic-Like and Procognitive Effects in Rodents, Revealing a Potential Therapeutic Agent for Schizophrenia.
J Pharmacol Exp Ther, 363 (2): 253-264. [PMID:28851764]
3. Poulter S, Austin N, Armstrong R, Barnes M, Bucknell SJ, Higueruelo A, Banerjee J, Mead A, Mould R, MacSweeney C et al.. (2023)
The Identification of GPR52 Agonist HTL0041178, a Potential Therapy for Schizophrenia and Related Psychiatric Disorders.
ACS Med Chem Lett, 14 (4): 499-505. [PMID:37077397]
4. Power ME, Fernandez NR, Oni OP, Kalia A, Rourke JL. (2024)
The non-nutritive sweetener sucralose increases β-arrestin signaling at the constitutively active orphan G protein-coupled receptor GPR52.
Can J Physiol Pharmacol, 102 (2): 116-127. [PMID:37748201]
5. Russell B, Barrus MM, Tremblay M, Ma L, Hrelja K, Wong C, Hynes TJ, Hobson S, Grottick AJ, Winstanley CA. (2021)
GPR52 agonists attenuate ropinirole-induced preference for uncertain outcomes.
Behav Neurosci, 135 (1): 8-23. [PMID:33119328]
6. Setoh M, Ishii N, Kono M, Miyanohana Y, Shiraishi E, Harasawa T, Ota H, Odani T, Kanzaki N, Aoyama K et al.. (2014)
Discovery of the first potent and orally available agonist of the orphan G-protein-coupled receptor 52.
J Med Chem, 57 (12): 5226-37. [PMID:24884590]
7. Setoh M, Tokumaru K, Nakahata T, Ishii N, Kori M. (2011)
Amide compound.
Patent number: WO2011078360. Assignee: Takeda Pharmaceutical Company Limited. Priority date: 24/12/2009. Publication date: 30/06/2011.
8. Stott LA, Brighton CA, Brown J, Mould R, Bennett KA, Newman R, Currinn H, Autore F, Higueruelo AP, Tehan BG et al.. (2021)
Characterisation of inverse agonism of the orphan-G protein-coupled receptor GPR52 by cannabinoid ligands Cannabidiol and O-1918.
Heliyon, 7 (6): e07201. [PMID:34189291]
9. Wang C, Zhang YF, Guo S, Zhao Q, Zeng Y, Xie Z, Xie X, Lu B, Hu Y. (2021)
GPR52 Antagonist Reduces Huntingtin Levels and Ameliorates Huntington's Disease-Related Phenotypes.
J Med Chem, 64 (2): 941-957. [PMID:33185430]